A Multi-Pathway Model We can think of this as a convergence of several mechanisms: L-cell activation from viral or microbial sensing Vagal signaling altered by cytokine release Gut-brain axis dysregulation, mirroring GLP-1 agonist effects Delayed motility from enteric nervous system inflammation Together, these pathways could produce a temporary GLP-1-like state during and shortly after the viral illness
Biotin, in plain English
The decreased risk of heart failure associated with SGLT-2 inhibitors may be imparted by their haemodynamic effects on the heart, such as reduced intravascular volume, improved arterial elasticity, and decreased cardiac preload and afterload.4041 Concerning their renoprotective effects, SGLT-2 inhibitors ameliorate hyperfiltration in the proximal tubules, which reduces intraglomerular pressure.42 Thus, the decreased cardiorenal risk associated with the combined use of GLP-1 receptor agonists and SGLT-2 inhibitors may be attributed to an additive effect, achieved by the distinct mechanisms and sites of action for these different drug classes
Holcomb, L
Though more chronic conditions will require a series of treatment for complete resolution, I have personally witnessed immediate relief from insomnia, digestive complaints, anxiety, and pain in my clinic
Obviously, its going to change and evolve
